AlzChem Group AG (ACT) AI Stock Analysis

• Market Cap: €1.32B
• Dividend Yield: 1.39%
• Average Volume (3M): 51.91K
• Price to Earnings (P/E): 24.3
• Beta (1Y): 0.48
• Revenue Growth: 2.51%
• EPS Growth: 56.13%
• Country: DE
• Employees: 1,541
• Sector: Basic Materials
• Sector Strength: 62
• Industry: Chemicals - Specialty
• EPS (TTM): 1.44
• Shares Outstanding: 10,176,335
• 10 Day Avg. Volume: 60,969
• 30 Day Avg. Volume: 51,909
• PEG Ratio: 4.84
• Price to Book (P/B): 5.58
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 17.06
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €118.75
• Price Target Upside: -8.79% Downside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 75 Outperform
• Price Target: €150.00 ▲(15.21%Upside)

AlzChem Group AG's overall stock score reflects its strong financial performance and positive technical indicators, balanced by a reasonable valuation. The lack of recent earnings call data and new corporate events leaves the financial and technical aspects as the primary drivers of this score.

AlzChem Group AG Business Overview & Revenue Model

Company Description

AlzChem Group AG, together with its subsidiaries, develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The company offers dietary supplements under the Creapure and Alipure brands; preparation of guanidinoacetic acid as a nutritional feed additives under the Creamino brand; creatine dietary supplements under the LIVADUR brand; products for pharmaceuticals under the Bioselect brand; curing agents, including accelerators for use in adhesives, powder coatings, printed circuit boards, and composites under the DYHARD name; and silicon nitride for ceramics, and electronics and solar applications under the SILZOT brand. It also provides fine and specialty chemicals, including products based on calcium carbide, calcium cyanamide, hydrogen cyanamide, dicyandiamide, guanidine, guanamines, and nitroguanidine, as well as aromatic and aliphatic nitriles; calcium cyanamide under the PERLKA name; germicide for use in pig pens under the ALZOGUR name; plant growth regulators under the Dormex and Sitofex name; and plant protection additives under the BREAK-THRU name. In addition, the company offers products for use in hot metal desulfurization and secondary metallurgy applications; and technical gases. Further, it provides chemical park operations and administrative services, as well as produces and distributes various infrastructure services. AlzChem Group AG was founded in 1908 and is based in Trostberg, Germany.

How the Company Makes Money

AlzChem Group AG generates its revenue through the production and sale of specialty chemicals. The company has diverse revenue streams, primarily derived from its key sectors: agriculture, where it supplies fertilizers and crop protection products; pharmaceuticals, providing high-purity chemicals for medical applications; metallurgy, offering additives and agents for metal processing; and electronics, supplying materials for advanced technological manufacturing. The company benefits from long-term contracts and partnerships with major industrial clients, which contribute to stable revenue flows. Additionally, its focus on innovation and development of high-value specialty products allows it to maintain competitive pricing, thereby enhancing profitability.

AlzChem Group AG Financial Statement Overview

Summary

Overall, AlzChem Group AG exhibits impressive financial health, characterized by strong revenue growth, efficient cost management, and improved profitability. The balance sheet reflects a stable financial position with manageable leverage. Cash flow metrics indicate robust cash generation, supporting sustainable growth.

Income Statement

AlzChem Group AG has demonstrated strong revenue growth, with a significant increase from 2023 to 2024. The gross profit margin is healthy, indicating efficient cost management. The net profit margin has improved, showcasing enhanced profitability. Both EBIT and EBITDA margins are strong, reflecting effective operational performance.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio, indicating manageable leverage. Return on equity has improved, demonstrating efficient use of equity capital. The equity ratio is stable, supporting asset financing through equity.

Cash Flow

AlzChem Group AG has shown robust growth in free cash flow, signifying improved operational efficiency. The operating cash flow to net income ratio is strong, indicating effective cash generation from operations. Free cash flow to net income ratio highlights the company's ability to convert earnings into cash flow.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
547.05M	554.23M	540.65M	542.22M	422.29M	379.26M
	Gross Profit
340.50M	339.26M	304.07M	282.72M	268.34M	250.58M
	EBIT
109.03M	173.35M	52.24M	39.09M	38.22M	31.01M
	EBITDA
103.04M	98.44M	81.75M	68.06M	61.89M	51.39M
	Net Income Common Stockholders
56.47M	54.08M	34.62M	30.05M	27.59M	19.69M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
12.93M	63.15M	13.92M	9.62M	8.73M	17.47M
	Total Assets
295.48M	483.83M	424.68M	422.86M	377.67M	354.30M
	Total Debt
47.61M	52.82M	62.49M	100.23M	55.64M	69.06M
	Net Debt
34.68M	-8.72M	50.60M	90.99M	47.36M	51.94M
	Total Liabilities
230.72M	276.36M	261.12M	276.91M	288.10M	285.64M
	Stockholders Equity
62.56M	205.54M	161.63M	144.01M	87.63M	66.89M
Cash Flow		Free Cash Flow
72.57M	62.05M	52.11M	-33.31M	14.48M	19.88M
	Operating Cash Flow
121.21M	105.15M	72.67M	-4.24M	43.02M	48.71M
	Investing Cash Flow
-37.20M	-30.99M	-20.55M	-28.51M	-28.48M	-28.83M
	Financing Cash Flow
-28.70M	-24.66M	-49.17M	33.65M	-23.62M	-11.73M

AlzChem Group AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 130.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:ACT, the sentiment is Positive. The current price of 130.2 is above the 20-day moving average (MA) of 124.53, above the 50-day MA of 112.36, and above the 200-day MA of 73.09, indicating a bullish trend. The MACD of 5.39 indicates Negative momentum. The RSI at 60.56 is Neutral, neither overbought nor oversold. The STOCH value of 85.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:ACT.

AlzChem Group AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACT	75 Outperform	€1.32B	24.35	29.46%	1.39%	2.51%	56.13%
Sector *	51 Neutral	$2.02B	-1.19	-21.37%	3.64%	2.88%	-30.57%
0MPT		€8.81B	16.58	11.49%	3.45%	―	―
0RBE		€11.06B	―	-6.00%	―	―	―
0QDS		€8.90B	29.81	3.25%	6.12%	―	―
LNXSF		$2.53B	―	-3.92%	0.36%	―	―
WKCMF		$3.52B	13.67	5.37%	3.77%	―	―